Tahsin, Farah
Morin, Kristen A.
Vojtesek, Frank
Marsh, David C.
Article History
Received: 14 December 2021
Accepted: 31 March 2022
First Online: 12 April 2022
Declarations
:
: The Laurentian University Research Ethics Board provided ethical approval for this study. These approvals included the circumstances within which this secondary analysis was conducted. All methods were carried out within ethical guideline. As a retrospective study with secondary analyses of anonymized data and no risk to participants, the Laurentian University Research Ethics Board waived the need for direct patient consent for this study. Hence, no direct patient consents were required for the study.
: Not applicable.
: Dr. David Marsh maintains the following roles: Chief Medical Director at CATC (Canadian Addiction Treatment Center), opioid agonist therapy provider. Dr. Marsh has no ownership stake in the CATC as a stipendiary employee. Therefore, we do not foresee any conflict of interest. The remaining authors have no conflicts declared.